| CARA Snapshot | |
|---|---|
| Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on itching and pain by selectively targeting kappa opioid receptors in the United States. The company is headquartered in Stamford, Connecticut. | |
| VALUATION DATA | |
| Market Capitalization | $36,714,400 | Price to Sales | 1.00 |
| Earnings per Share | $-2.1900 |
| PE Ratio | None |
| PRICE DATA | |
| Most Recent Close | $0.7000 |
| 52 Week High | $1.992 |
| 52 Week Low | $0.732 |
| 50-Day Moving Average | $12.05 |
| 200-Day Moving Average | $0.45 |
| All data are from Alpha Vantage as of today. For more infomation on CARA see Stock Dividend, Valuation, Price and Financial Data for Investors | |
Custom Search